{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,26]],"date-time":"2026-08-26T12:23:25Z","timestamp":1787747005381,"version":"build-2784847793"},"reference-count":90,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2026,7,16]],"date-time":"2026-07-16T00:00:00Z","timestamp":1784160000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,7,16]],"date-time":"2026-07-16T00:00:00Z","timestamp":1784160000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"name":"institutional support","award":["RVO:68081715"],"award-info":[{"award-number":["RVO:68081715"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Biometals"],"published-print":{"date-parts":[[2026,10]]},"DOI":"10.1007\/s10534-026-00855-1","type":"journal-article","created":{"date-parts":[[2026,7,16]],"date-time":"2026-07-16T02:57:35Z","timestamp":1784170655000},"page":"1449-1465","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Triorganotin compounds as emerging nuclear retinoid X receptor ligands and their implications in cancer"],"prefix":"10.1007","volume":"39","author":[{"given":"Janette","family":"Bobalova","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dana","family":"Strouhalova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,7,16]]},"reference":[{"key":"855_CR1","doi-asserted-by":"publisher","DOI":"10.1186\/s40001-025-03073-6","volume":"30","author":"MA Abdel-Rasol","year":"2025","unstructured":"Abdel-Rasol MA, El-Sayed WM (2025) Nuclear receptors in metabolic, inflammatory, and oncologic diseases: mechanisms, therapeutic advances, and future directions. Eur J Med Res 30:843","journal-title":"Eur J Med Res"},{"key":"855_CR2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ccr.2023.215579","volume":"501","author":"S Abdolmaleki","year":"2024","unstructured":"Abdolmaleki S, Aliabadi A, Khaksar S (2024) Riding the metal wave: a review of the latest developments in metal-based anticancer agents. Coord Chem Rev 501:215579","journal-title":"Coord Chem Rev"},{"key":"855_CR3","doi-asserted-by":"publisher","first-page":"2571","DOI":"10.3390\/molecules23102571","volume":"23","author":"JO Adeyemi","year":"2018","unstructured":"Adeyemi JO, Onwudiwe DC (2018) Organotin (IV) dithiocarbamate complexes: chemistry and biological activity. Molecules 23:2571","journal-title":"Molecules"},{"key":"855_CR4","doi-asserted-by":"publisher","first-page":"500","DOI":"10.1016\/j.drudis.2009.02.002","volume":"14","author":"A Alama","year":"2009","unstructured":"Alama A, Tasso B, Novelli F, Sparatore F (2009) Organometallic compounds in oncology: implications of novel organotins as antitumor agents. Drug Discov Today 14:500\u2013508","journal-title":"Drug Discov Today"},{"key":"855_CR5","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1016\/j.ica.2014.07.053","volume":"423","author":"MK Amir","year":"2014","unstructured":"Amir MK, Khan S, Rehman ZU, Shah A, Butler IS (2014) Anticancer activity of organotin(IV) carboxylates. Inorg Chim Acta 423:14\u201325","journal-title":"Inorg Chim Acta"},{"key":"855_CR6","doi-asserted-by":"publisher","DOI":"10.1016\/j.jinorgbio.2020.111022","volume":"206","author":"B-H An","year":"2020","unstructured":"An B-H, Zhang R-F, Du X-M, Li Q-L, Chen S, Huang H-L, Ma C-L (2020) Novel triorganotin complexes based on phosphonic acid ligands: syntheses,structures and in vitro cytostatic aktivity. J Inorg Biochem 206:111022","journal-title":"J Inorg Biochem"},{"key":"855_CR7","doi-asserted-by":"publisher","first-page":"770e","DOI":"10.1016\/j.ejmech.2016.09.061","volume":"125","author":"T Anasamy","year":"2017","unstructured":"Anasamy T, Thy CK, Lo KM, Chee CF, Yeap SK, Kamalidehghan B, Chung LY (2017) Tribenzyltin carboxylates as anticancer drug candidates: effect on the cytotoxicity, motility and invasiveness of breast cancer cell lines. Eur J Med Chem 125:770e\u20137783","journal-title":"Eur J Med Chem"},{"key":"855_CR8","doi-asserted-by":"publisher","DOI":"10.1002\/aoc.6089","volume":"35","author":"T Anasamy","year":"2020","unstructured":"Anasamy T, Chee CF, Wong YF (2020a) Triorganotin complexes in cancer chemotherapy: mechanistic insights and future perspectives. Appl Organomet Chem 35:e6089","journal-title":"Appl Organomet Chem"},{"key":"855_CR9","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejps.2019.105140","volume":"142","author":"T Anasamy","year":"2020","unstructured":"Anasamy T, Chee CF, Kiew LV, Chung LY (2020b) In vivo antitumour properties of tribenzyltin carboxylates in a 4T1 murine metastatic mammary tumour model: enhanced efficacy by PLGA nanoparticles. Eur J Pharm Sci 142:105140","journal-title":"Eur J Pharm Sci"},{"key":"855_CR10","doi-asserted-by":"publisher","DOI":"10.3389\/fchem.2021.657599","volume":"9","author":"SNS Annuar","year":"2021","unstructured":"Annuar SNS, Kamaludin NF, Awang N, Chan KM (2021) Cellular basis of organotin(IV) derivatives as anticancer metallodrugs: a review. Front Chem 9:657599","journal-title":"Front Chem"},{"key":"855_CR11","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-025-31015-z","volume":"15","author":"SNS Annuar","year":"2025","unstructured":"Annuar SNS, Kamaludin NF, Awang N, Chan KM (2025) Mitochondrial apoptosis and G0\/G1-phase blockade: key mechanisms underlying triphenyltin(IV) dithiocarbamate-mediated cytotoxicity in human lymphoblastic leukemia cells. Sci Rep 15:44310","journal-title":"Sci Rep"},{"key":"855_CR12","doi-asserted-by":"publisher","first-page":"763","DOI":"10.1081\/DMR-200033490","volume":"36","author":"KE Appel","year":"2004","unstructured":"Appel KE (2004) Organotin compounds: toxicokinetic aspects. Drug Metab Rev 36:763\u2013786","journal-title":"Drug Metab Rev"},{"key":"855_CR13","doi-asserted-by":"publisher","DOI":"10.3390\/cancers12092623","volume":"12","author":"G Augimeri","year":"2020","unstructured":"Augimeri G, Giordano C, Gelsomino L, Plastina P, Barone I, Catalano S, And\u00f2 S, Bonofiglio D (2020) The role of PPAR\u03b3 ligands in breast cancer: from basic research to clinical studies. Cancers 12:2623","journal-title":"Cancers"},{"key":"855_CR14","doi-asserted-by":"publisher","first-page":"414","DOI":"10.1016\/j.crvi.2017.08.002","volume":"340","author":"P Balaguer","year":"2017","unstructured":"Balaguer P, Delfosse V, Grimaldi M, Bourguet W (2017) Structural and functional evidences for the interactions between nuclear hormone receptors and endocrine disruptors at low doses. CR Biol 340:414\u2013420","journal-title":"CR Biol"},{"key":"855_CR15","doi-asserted-by":"publisher","first-page":"599","DOI":"10.1097\/00001813-200207000-00006","volume":"13","author":"F Barbieri","year":"2002","unstructured":"Barbieri F, Viale M, Sparatore F, Schettini G, Favre A, Bruzzo C, Novelli F, Alama A (2002) Antitumor activity of a new orally active organotin compound: a preliminary study in murine tumor models. Anticancer Drugs 13:599\u2013604","journal-title":"Anticancer Drugs"},{"key":"855_CR16","doi-asserted-by":"publisher","first-page":"3","DOI":"10.21101\/cejph.a3412","volume":"15","author":"J Brtko","year":"2007","unstructured":"Brtko J (2007) Role of retinoids and their cognate nuclear receptors in breast cancer chemoprevention. Cent Eur J Public Health 15:3\u20136","journal-title":"Cent Eur J Public Health"},{"key":"855_CR17","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1016\/j.toxlet.2015.02.009","volume":"234","author":"J Brtko","year":"2015","unstructured":"Brtko J, Dvorak Z (2015) Triorganotin compounds - ligands for \u201crexinoid\u201d inducible transcription factors: biological effects. Toxicol Lett 234:50\u201358","journal-title":"Toxicol Lett"},{"key":"855_CR18","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1016\/j.biochi.2020.09.027","volume":"179","author":"J Brtko","year":"2020","unstructured":"Brtko J, Dvorak Z (2020) Natural and synthetic retinoid X receptor ligands and their role in selected nuclear receptor action. Biochimie 179:157\u2013168","journal-title":"Biochimie"},{"key":"855_CR19","doi-asserted-by":"publisher","first-page":"411","DOI":"10.1007\/s00775-025-02117-w","volume":"30","author":"DA Burmistrova","year":"2025","unstructured":"Burmistrova DA, Pomortseva NP, Berberova NT, Almyasheva NR, Kiskin MA, Poddel\u2019sky AI, Vashurin AS, Smolyaninov IV (2025) Organotin(IV) carboxylates\u2014derivatives of bexarotene: synthesis, characterization, anti\/prooxidant activity, and high cytotoxicity. JBIC J Biol Inorg Chem 30:411\u2013424","journal-title":"JBIC J Biol Inorg Chem"},{"key":"855_CR20","doi-asserted-by":"publisher","DOI":"10.1016\/j.ica.2022.120929","volume":"537","author":"A Celesia","year":"2022","unstructured":"Celesia A, Fiore T, Di Liberto D, Giuliano M, Pellerito C, Emanuele S (2022) Bortezomib potentiates the antitumor effect of tributyltin(IV) ferulate in colon cancer cells exacerbating ER stress and promoting apoptosis. Inorg Chim Acta 537:120929","journal-title":"Inorg Chim Acta"},{"key":"855_CR21","doi-asserted-by":"publisher","first-page":"R546","DOI":"10.1186\/bcr913","volume":"6","author":"DL Crowe","year":"2004","unstructured":"Crowe DL, Chandraratna RA (2004) A retinoid X receptor (RXR)-selective retinoid reveals that RXR-\u03b1 is potentially a therapeutic target in breast cancer cell lines, and that it potentiates antiproliferative and apoptotic responses to peroxisome proliferator-activated receptor ligands. Breast Cancer Res 6:R546-555","journal-title":"Breast Cancer Res"},{"key":"855_CR22","doi-asserted-by":"publisher","DOI":"10.3390\/cells12081201","volume":"12","author":"Y Dauwe","year":"2023","unstructured":"Dauwe Y, Mary L, Oliviero F, Grimaldi M, Balaguer P, Gayrard V, Mselli-Lakhal L (2023) Steatosis and metabolic disorders associated with synergistic activation of the CAR\/RXR heterodimer by pesticides. Cells 12:1201","journal-title":"Cells"},{"key":"855_CR23","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1016\/j.bbalip.2011.09.014","volume":"1821","author":"MI Dawson","year":"2012","unstructured":"Dawson MI, Xia Z (2012) The retinoid X receptors and their ligands. Biochim Biophys Acta 1821:21\u201356","journal-title":"Biochim Biophys Acta"},{"key":"855_CR24","doi-asserted-by":"publisher","first-page":"1372","DOI":"10.1002\/med.21578","volume":"39","author":"NR de Almeida","year":"2020","unstructured":"de Almeida NR, Conda-Sheridan M (2020) A review of the molecular design and biological activities of RXR agonists. Med Res Rev 39:1372\u20131397","journal-title":"Med Res Rev"},{"key":"855_CR25","doi-asserted-by":"publisher","DOI":"10.1002\/aoc.5815","volume":"34","author":"J Devi","year":"2020","unstructured":"Devi J, Yadav J, Kumar D, Jindal DK, Basu B (2020) Synthesis, spectral analysis and in vitro cytotoxicity of diorganotin (IV) complexes derived from indole-3-butyric hydrazide. Appl Organomet Chem 34:e5815","journal-title":"Appl Organomet Chem"},{"key":"855_CR26","doi-asserted-by":"publisher","first-page":"164","DOI":"10.2174\/1871520622666220520095549","volume":"23","author":"J Devi","year":"2023","unstructured":"Devi J, Boora A, Rani M, Arora T (2023) Recent advancements in organotin(IV) complexes as potent cytotoxic agents. Anti-Cancer Agents Med Chem 23:164\u2013191","journal-title":"Anti-Cancer Agents Med Chem"},{"key":"855_CR27","doi-asserted-by":"publisher","first-page":"R169","DOI":"10.1530\/JME-16-0082","volume":"58","author":"TB Doan","year":"2017","unstructured":"Doan TB, Graham JD, Clarke CL (2017) Emerging functional roles of nuclear receptors in breast cancer. J Mol Endocrinol 58:R169\u2013R190","journal-title":"J Mol Endocrinol"},{"key":"855_CR28","doi-asserted-by":"publisher","DOI":"10.1016\/j.molstruc.2024.137553","volume":"1303","author":"X-M Du","year":"2024","unstructured":"Du X-M, Ma J-W, Ru J, Cui Y, Ma C-L (2024) Anticancer effect of organotin complexes derived from 2,6-naphthalenedicarboxylic acid by enhancing the ROS generation. J Mol Struct 1303:137553","journal-title":"J Mol Struct"},{"key":"855_CR29","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1016\/j.cell.2014.03.012","volume":"157","author":"RM Evans","year":"2014","unstructured":"Evans RM, Mangelsdorf DJ (2014) Nuclear receptors, RXR, and the big bang. Cell 157:255\u2013266","journal-title":"Cell"},{"key":"855_CR30","doi-asserted-by":"publisher","first-page":"4195","DOI":"10.1021\/jf3050186","volume":"61","author":"M Ferreira","year":"2013","unstructured":"Ferreira M, Blanco L, Garrido A, Vieites JM, Cabado AG (2013) In vitro approaches to evaluate toxicity induced by organotin compounds tributyltin (TBT), dibutyltin (DBT), and monobutyltin (MBT) in neuroblastoma cells. J Agric Food Chem 61:4195\u20134203","journal-title":"J Agric Food Chem"},{"key":"855_CR31","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1016\/j.poly.2014.05.001","volume":"79","author":"IP Ferreira","year":"2014","unstructured":"Ferreira IP, de Lima GM, Paniago EB, Rocha WR, Takahashi JA, Pinheiro CB, Ardisson JD (2014) Design, structural and spectroscopic elucidation, and the in vitro biological activities of new triorganotin dithiocarbamates\u2014part II. Polyhedron 79:161\u2013169","journal-title":"Polyhedron"},{"key":"855_CR32","doi-asserted-by":"publisher","first-page":"727","DOI":"10.1016\/j.tiv.2015.02.007","volume":"29","author":"M Fickova","year":"2015","unstructured":"Fickova M, Macho L, Brtko J (2015) A comparison of the effects of tributyltin chloride and triphenyltin chloride on cell proliferation, proapoptotic P53, bax, and antiapoptotic BCL-2 protein levels in human breast cancer MCF-7 cell line. Toxicol in Vitro 29:727\u2013731","journal-title":"Toxicol in Vitro"},{"key":"855_CR33","doi-asserted-by":"publisher","first-page":"594","DOI":"10.3390\/biom10040594","volume":"10","author":"E Fonseca","year":"2020","unstructured":"Fonseca E, Ruivo R, Borges D, Franco JN, Santos MM, Filipe L, Castro C (2020) Of retinoids and organotins: the evolution of the retinoid X receptor in metazoa. Biomolecules 10:594","journal-title":"Biomolecules"},{"key":"855_CR34","doi-asserted-by":"publisher","DOI":"10.1016\/j.molstruc.2024.139435","volume":"1319","author":"B Hanifa","year":"2025","unstructured":"Hanifa B, Bibi N, Ullah Z, Sirajuddin M, Tiekink ERT, Khan IN, Tariq M, AlObaid A, Bari A (2025) Synthesis, spectral, in silico\/molecular docking and pharmacological studies of biologically potent triorganotin(IV) carboxylates. J Mol Struct 1319:139435","journal-title":"J Mol Struct"},{"key":"855_CR35","doi-asserted-by":"publisher","DOI":"10.1016\/j.ccr.2025.216582","volume":"534","author":"S He","year":"2025","unstructured":"He S, Alhumaydhi FA, Abdulmonem WAI, Aljasirf MA, Ibrahim M (2025) Organotin(IV) complexes: emerging frontiers in anticancer therapeutics and bioimaging applications. Coord Chem Rev 534:216582","journal-title":"Coord Chem Rev"},{"key":"855_CR36","doi-asserted-by":"publisher","first-page":"1180","DOI":"10.1039\/c5mt00086f","volume":"7","author":"Y Hiromori","year":"2015","unstructured":"Hiromori Y, Aoki A, Nishikawa J, Nagase H, Nakanishi T (2015) Transactivation of the human retinoid X receptor by organotins: use of site-directed mutagenesis to identify critical amino acid residues for organotin-induced transactivation. Metallomics 7:1180\u20131188","journal-title":"Metallomics"},{"key":"855_CR37","doi-asserted-by":"publisher","first-page":"1596","DOI":"10.1248\/bpb.b16-00186","volume":"39","author":"Y Hiromori","year":"2016","unstructured":"Hiromori Y, Ido A, Aoki A, Kimura T, Nagase H, Nakanishi T (2016) Ligand activity of group 15 compounds possessing triphenyl substituent for the RXR and PPAR\u03b3 nuclear receptors. Biol Pharm Bull 39:1596\u20131603","journal-title":"Biol Pharm Bull"},{"key":"855_CR38","doi-asserted-by":"publisher","first-page":"1515","DOI":"10.1111\/cas.12802","volume":"106","author":"G-L Huang","year":"2015","unstructured":"Huang G-L, Zhang W, Ren H-Y, Shen X-Y, Chen Q-X, Shen D-Y (2015) Retinoid X receptor a enhances humancholangiocarcinoma growth through simultaneousactivation of Wnt\u2044b-catenin and nuclear factor-kBpathways. Cancer Sci 106:1515\u20131523","journal-title":"Cancer Sci"},{"key":"855_CR39","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-018-24076-w","volume":"8","author":"CF Huang","year":"2018","unstructured":"Huang CF, Yang CY, Tsai JR, Wu CT, Liu SH, Lan KC (2018) Low-dose tributyltin exposure induces an oxidative stress-triggered JNK-related pancreatic \u03b2-cell apoptosis and a reversible hypoinsulinemic hyperglycemia in mice. Sci Rep 8:5734","journal-title":"Sci Rep"},{"key":"855_CR40","doi-asserted-by":"publisher","DOI":"10.1016\/j.bioorg.2023.106477","volume":"135","author":"G Huang","year":"2023","unstructured":"Huang G, Cierpicki T, Grembecka J (2023) 2-Aminobenzothiazoles in anticancer drug design and discovery. Bioorg Chem 135:106477","journal-title":"Bioorg Chem"},{"key":"855_CR41","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1016\/j.toxlet.2017.07.879","volume":"279","author":"L Hunakova","year":"2017","unstructured":"Hunakova L, Brtko J (2017) Sn- and Ge- triorganometallics exert different cytotoxicity and modulation of migration in triple-negative breast cancer cell line MDA-MB-231. Toxicol Lett 279:16\u201321","journal-title":"Toxicol Lett"},{"key":"855_CR42","doi-asserted-by":"publisher","first-page":"6701","DOI":"10.1007\/s13277-015-4524-6","volume":"37","author":"L Hunakova","year":"2016","unstructured":"Hunakova L, Macejova D, Toporova L, Brtko J (2016) Anticancer effects of tributyltin chloride and triphenyltin chloride in human breast cancer cell lines MCF-7 and MDA-MB-231. Tumor Biol 37:6701\u20136708","journal-title":"Tumor Biol"},{"key":"855_CR43","doi-asserted-by":"publisher","DOI":"10.3390\/ijms20051198","volume":"20","author":"L Hunakova","year":"2019","unstructured":"Hunakova L, Horvathova E, Majerova K, Bobal P, Otevrel J, Brtko J (2019) Genotoxic effects of tributyltin and triphenyltin isothiocyanates, cognate RXR ligands: comparison in human breast carcinoma MCF 7 and MDA-MB-231 cells. Int J Mol Sci 20:1198","journal-title":"Int J Mol Sci"},{"key":"855_CR44","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1007\/s12032-022-01692-1","volume":"39","author":"L Hunakova","year":"2022","unstructured":"Hunakova L, Horvathova E, Matuskova M, Bobal P, Otevrel J, Brtko J (2022) In vitro antiproliferative and cytotoxic activities of novel triphenyltin isoselenocyanate in human breast carcinoma cell lines MCF 7 and MDA-MB-231. Med Onc 39:99","journal-title":"Med Onc"},{"key":"855_CR45","doi-asserted-by":"publisher","first-page":"776","DOI":"10.1038\/s41416-019-0589-0","volume":"121","author":"C Joseph","year":"2019","unstructured":"Joseph C, Al-Izzi S, Alsaleem M, Kurozumi S, Toss MS, Arshad M, Goh FQ, Alshankyty IM, Aleskandarany MA, Ali S, Ellis IO, Mongan NP, Green AR, Rakha EA (2019) Retinoid X receptor gamma (RXRG) is an independent prognostic biomarker in ER-positive invasive breast cancer. Br J Cancer 121:776\u2013785","journal-title":"Br J Cancer"},{"key":"855_CR46","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1186\/s40478-024-01904-x","volume":"12","author":"GDS Kasheke","year":"2024","unstructured":"Kasheke GDS, Hendy BAM, Dorighello GG, Uccelli NA, Gothi\u00e9 J-DM, Novorolsky RJ, Oulton MJ, Asainayagam J, Makarov AI, Fraser KS, Vuligonda V, Sanders ME, Kennedy TE, Robertson GS (2024) Selective retinoid X receptor agonism promotes functional recovery and myelin repair in experimental autoimmune encephalomyelitis. Acta Neuropathol Commun 12:197","journal-title":"Acta Neuropathol Commun"},{"key":"855_CR47","first-page":"999","volume":"126","author":"V Kashyap","year":"2013","unstructured":"Kashyap V, Laursen KB, Brenet F, Viale AJ, Scandura JM, Gudas LJ (2013) RAR\u03b3 is essential for retinoic acid induced chromatin remodeling and transcriptional activation in embryonic stem cells. J Cell Sci 126:999\u20131008","journal-title":"J Cell Sci"},{"key":"855_CR48","doi-asserted-by":"publisher","first-page":"110436","DOI":"10.1016\/j.mce.2019.04.016","volume":"491","author":"W Kr\u0119\u017cel","year":"2019","unstructured":"Kr\u0119\u017cel W, R\u00fchl R, de Lera AR (2019) Alternative retinoid X receptor (RXR) ligands. Mol Cell Endocrinol 491:110436","journal-title":"Mol Cell Endocrinol"},{"key":"855_CR49","first-page":"65","volume-title":"Reviews of environmental contamination and toxicology","author":"L Lagadic","year":"2017","unstructured":"Lagadic L, Katsiadaki I, Biever R, Guiney PD, Karouna-Renier N, Schwarz T, Meador JP (2017) Tributyltin: advancing the science on assessing endocrine disruption with an unconventional endocrine-disrupting compound. In: de Voogt P (ed) Reviews of environmental contamination and toxicology, vol 245. Springer, Cham, pp 65\u2013127"},{"key":"855_CR50","doi-asserted-by":"publisher","first-page":"367","DOI":"10.1038\/embor.2009.8","volume":"10","author":"A le Maire","year":"2009","unstructured":"le Maire A, Grimaldi M, Roecklin D, Dagnino S, Vivat-Hannah V, Balaguer P, Bourguet W (2009) Activation of RXR-PPAR heterodimers by organotin environmental endocrine disruptors. EMBO Rep 10:367\u2013373","journal-title":"EMBO Rep"},{"key":"855_CR51","doi-asserted-by":"publisher","DOI":"10.1016\/j.pharmthera.2023.108561","volume":"252","author":"AS Leal","year":"2023","unstructured":"Leal AS, Hung P-Y, Chowdhury AS, Liby KT (2023) Retinoid X Receptor agonists as selective modulators of the immune system for the treatment of cancer. Pharmacol Ther 252:108561","journal-title":"Pharmacol Ther"},{"key":"855_CR52","doi-asserted-by":"publisher","first-page":"854","DOI":"10.1021\/acsptsci.4c00719","volume":"8","author":"M Lewandowski","year":"2025","unstructured":"Lewandowski M, Busch R, Marschner JA, Merk D (2025) Comparative evaluation and profiling of chemical tools for the nuclear hormone receptor family. ACS Pharmacol Transl Sci 8:854\u2013870","journal-title":"ACS Pharmacol Transl Sci"},{"key":"855_CR53","doi-asserted-by":"publisher","first-page":"1380","DOI":"10.1038\/sj.bjc.6604320","volume":"98","author":"Y Li","year":"2008","unstructured":"Li Y, Zhang Y, Hill J, Kim H-T, Shen Q, Bissonnette RP, Lamph WW, Brown PH (2008) The rexinoid, bexarotene, prevents the development of premalignant lesions in MMTV-erbB2 mice. Br J Cancer 98:1380\u20131388","journal-title":"Br J Cancer"},{"key":"855_CR54","doi-asserted-by":"publisher","first-page":"721","DOI":"10.2174\/1568026616666160617090702","volume":"17","author":"KT Liby","year":"2017","unstructured":"Liby KT, Sporn MB (2017) Rexinoids for prevention and treatment of cancer: opportunities and challenges. Curr Top Med Chem 17:721\u2013730","journal-title":"Curr Top Med Chem"},{"key":"855_CR55","doi-asserted-by":"publisher","first-page":"21685","DOI":"10.18632\/oncotarget.3942","volume":"6","author":"M-L Lin","year":"2015","unstructured":"Lin M-L, Patel H, Remenyi J, Banerji CRS, Lai C-F, Periyasamy M, Lombardo Y, Busonero C, Ottaviani S, Passey A, Quinlan PR, Purdie CA, Jordan LB, Thompson AM, Finn RS, Rueda OM, Caldas C, Gil J, Coombes RC, Fuller-Pace FV, Teschendorff AE, Buluwela L, Ali S (2015) Expression profiling of nuclear receptors in breast cancer identifies TLX as a mediator of growth and invasion in triple-negative breast cancer. Oncotarget 6:21685\u201321703","journal-title":"Oncotarget"},{"key":"855_CR56","doi-asserted-by":"publisher","first-page":"310","DOI":"10.1002\/path.4001","volume":"228","author":"R-Z Liu","year":"2012","unstructured":"Liu R-Z, Graham K, Glubrecht DD, Lai R, Mackey JR, Godbout R (2012) A fatty acid-binding protein 7\/RXR\u03b2 pathway enhances survivaland proliferation in triple-negative breast cancer. J Pathol 228:310\u2013321","journal-title":"J Pathol"},{"key":"855_CR57","doi-asserted-by":"publisher","first-page":"481","DOI":"10.4149\/gpb_2017038","volume":"36","author":"D Macejova","year":"2017","unstructured":"Macejova D, Toporova L, Brtko J (2017) Effects of natural ligands and synthetic triorganotin compounds of nuclear retinoid X receptors in human MCF-7 breast cancer cell line. Gen Physiol Biophys 36:481\u2013484","journal-title":"Gen Physiol Biophys"},{"key":"855_CR58","doi-asserted-by":"publisher","first-page":"3091","DOI":"10.1007\/s11010-023-04914-w","volume":"479","author":"D Macejova","year":"2024","unstructured":"Macejova D, Kollar J, Bobal P, Otevrel J, Schuster D, Brtko J (2024) Triphenyltin isoselenocyanate: a novel nuclear retinoid X receptor ligand with antiproliferative and cytotoxic properties in cell lines derived from human breast cancer. Mol Cell Biochem 479:3091\u20133106","journal-title":"Mol Cell Biochem"},{"key":"855_CR59","doi-asserted-by":"publisher","DOI":"10.1016\/j.tiv.2025.106153","volume":"110","author":"D Macejova","year":"2026","unstructured":"Macejova D, Kollar J, Dvorak Z, Schuster D, Brtko J (2026) Tributyltin propionate and tributyltin salicylate represent novel RXR ligands: effects on transcriptional activity of thyroid hormone receptor and vitamin D3 receptor. Toxicol in Vitro 110:106153","journal-title":"Toxicol in Vitro"},{"key":"855_CR60","doi-asserted-by":"publisher","DOI":"10.1155\/2015\/254560","author":"DP Marciano","year":"2015","unstructured":"Marciano DP, Kuruvilla DS, Pascal BD, Griffin PR (2015) Identification of bexarotene as a PPAR\u03b3 antagonist with HDX. PPAR Res. https:\/\/doi.org\/10.1155\/2015\/254560","journal-title":"PPAR Res"},{"key":"855_CR61","doi-asserted-by":"publisher","first-page":"507","DOI":"10.3389\/fphar.2017.00507","volume":"8","author":"FA Milton","year":"2017","unstructured":"Milton FA, Lacerda MG, Sinoti SBP, Mesquita PG, Prakasan D, Coelho MS, de Lima CL, Martini AG, Pazzine GT, Borin MF, Amato AA, Neves FAR (2017) Dibutyltin compounds effects on PPAR\u03b3\/RXR\u03b1 activity, adipogenesis, and inflammation in mammalians cells. Front Pharmacol 8:507","journal-title":"Front Pharmacol"},{"key":"855_CR62","doi-asserted-by":"publisher","DOI":"10.3389\/fmed.2023.1200947","volume":"10","author":"CL Moyer","year":"2023","unstructured":"Moyer CL, Brown PH (2023) Targeting nuclear hormone receptors for the prevention of breast cancer. Front Med 10:1200947","journal-title":"Front Med"},{"key":"855_CR63","doi-asserted-by":"publisher","first-page":"2558","DOI":"10.1158\/1078-0432.CCR-23-3839","volume":"30","author":"CL Moyer","year":"2024","unstructured":"Moyer CL, Lanier A, Qian J, Coleman D, Hill J, Vuligonda V, Sanders ME, Mazumdar A, Brown PH (2024) IRX4204 induces senescence and cell death in HER2-positive breast cancer and synergizes with anti-HER2 therapy. Clin Cancer Res 30:2558\u20132570","journal-title":"Clin Cancer Res"},{"key":"855_CR64","doi-asserted-by":"publisher","first-page":"2502","DOI":"10.1210\/me.2004-0397","volume":"19","author":"T Nakanishi","year":"2005","unstructured":"Nakanishi T, Nishikawa J, Hiromori Y, Yokoyama H, Koyanagi M, Takasuga S, Ishizaki J, Watanabe M, Isa S, Utoguchi N, Itoh N, Kohno Y, Nishihara T, Tanaka K (2005) Trialkyltin compounds bind retinoid X receptor to alter human placental endocrine functions. Mol Endocrinol 19:2502\u20132516","journal-title":"Mol Endocrinol"},{"key":"855_CR65","doi-asserted-by":"publisher","first-page":"598","DOI":"10.1002\/aoc.1436","volume":"22","author":"M Nath","year":"2008","unstructured":"Nath M (2008) Toxicity and the cardiovascular activity of organotin compounds: a review. Appl Organomet Chem 22:598\u2013612","journal-title":"Appl Organomet Chem"},{"key":"855_CR66","doi-asserted-by":"publisher","first-page":"599","DOI":"10.2147\/DDDT.S119488","volume":"11","author":"U Ndagi","year":"2017","unstructured":"Ndagi U, Mhlongo N, Soliman ME (2017) Metal complexes in cancer therapy\u2014an update from drug design perspective. Drug des Devel Ther 11:599\u2013616","journal-title":"Drug des Devel Ther"},{"key":"855_CR67","doi-asserted-by":"publisher","DOI":"10.1016\/j.jinorgbio.2025.112991","volume":"272","author":"Z Pan","year":"2025","unstructured":"Pan Z, Zhong W, Li Y, Lin S, Chen S, Tian W (2025) Synthesis and anticancer activity of six tricyclohexyltin cinnamate complexes. J Inorg Biochem 272:112991","journal-title":"J Inorg Biochem"},{"key":"855_CR68","doi-asserted-by":"publisher","first-page":"1059","DOI":"10.1093\/jnci\/91.12.1059","volume":"91","author":"E Picard","year":"1999","unstructured":"Picard E, Seguin C, Monhoven N, Rochette-Egly C, Siat J, Borrelly J, Martinet Y, Martinet N, Vignaud JM (1999) Expression of retinoid receptor genes and proteins in non-small-cell lung cancer. J Natl Cancer Inst 91:1059\u20131066","journal-title":"J Natl Cancer Inst"},{"key":"855_CR69","doi-asserted-by":"publisher","first-page":"595","DOI":"10.3390\/biom13040595","volume":"13","author":"I Predarska","year":"2023","unstructured":"Predarska I, Saoud M, Morgan I, L\u00f6nnecke P, Kaluderovic GN, Hey-Hawkins E (2023) Triphenyltin(IV) carboxylates with exceptionally high cytotoxicity against different breast cancer cell lines. Biomolecules 13:595","journal-title":"Biomolecules"},{"key":"855_CR70","doi-asserted-by":"publisher","DOI":"10.1016\/j.taap.2022.116209","volume":"453","author":"Y Pu","year":"2022","unstructured":"Pu Y, Ticiani E, Pearl S, Martin D, Veiga-Lopez A (2022) The organotin triphenyltin disrupts cholesterol signaling in mammalian ovarian steroidogenic cells through a combination of LXR and RXR modulation. Toxicol Appl Pharmacol 453:116209","journal-title":"Toxicol Appl Pharmacol"},{"key":"855_CR71","doi-asserted-by":"publisher","first-page":"4499","DOI":"10.1039\/D0RA06695H","volume":"11","author":"F Rashid","year":"2021","unstructured":"Rashid F, Uddin N, Ali S, Haider A, Tirmizi SA, Diaconescu PL, Iqba J (2021) New triorganotin(IV) compounds with aromatic carboxylate ligands: synthesis and evaluation of the pro-apoptotic mechanism. RSC Adv 11:4499\u20134514","journal-title":"RSC Adv"},{"key":"855_CR72","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1210\/endocr\/bqad021","volume":"164","author":"X-M Ren","year":"2023","unstructured":"Ren X-M, Chang RC, Huang Y, Amato AA, Carivenc C, Grimaldi M, Kuo Y, Balaguer P, Bourguet W, Blumberg B (2023) 2,4-Di-tert-butylphenol induces adipogenesis in human mesenchymal stem cells by activating retinoid X receptors. Endocrinology 164:1\u201311","journal-title":"Endocrinology"},{"key":"855_CR73","doi-asserted-by":"publisher","DOI":"10.3390\/cells12060864","volume":"12","author":"M Schubert","year":"2023","unstructured":"Schubert M, Germain P (2023) Retinoic acid and retinoid X receptors. Cells 12:864","journal-title":"Cells"},{"key":"855_CR74","doi-asserted-by":"publisher","first-page":"2027","DOI":"10.1007\/s12035-021-02709-y","volume":"59","author":"S Sharma","year":"2022","unstructured":"Sharma S, Shen T, Chitranshi N, Gupta V, Basavarajappa D, Sarkar S, Mirzaei M, You Y, Krezel W, Graham SL, Gupta V (2022) Retinoid X receptor: cellular and biochemical roles of nuclear receptor with a focus on neuropathological involvement. Mol Neurobiol 59:2027\u20132050","journal-title":"Mol Neurobiol"},{"key":"855_CR75","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1038\/s41580-018-0089-8","volume":"20","author":"R Singh","year":"2019","unstructured":"Singh R, Letai A, Sarosiek K (2019) Regulation of apoptosis in health and disease: the balancing act of BCL-2 family proteins. Nat Rev Mol Cell Biol 20:175\u2013193","journal-title":"Nat Rev Mol Cell Biol"},{"key":"855_CR76","doi-asserted-by":"publisher","first-page":"6665","DOI":"10.2174\/1381612822666160906143249","volume":"22","author":"M Sirajuddin","year":"2016","unstructured":"Sirajuddin M, Ali S (2016) Organotin(IV) carboxylates as promising potential drug candidates in the field of cancer chemotherapy. Curr Pharm des 22:6665\u20136681","journal-title":"Curr Pharm des"},{"key":"855_CR77","doi-asserted-by":"publisher","DOI":"10.1016\/j.steroids.2021.108798","volume":"167","author":"MEK Stathopoulou","year":"2021","unstructured":"Stathopoulou MEK, Zoupanou N, Banti CN, Douvalis AP, Papachristodoulou C, Marousis KD, Spyroulias GA, Mavromoustakos T, Hadjikakou SK (2021) Organotin derivatives of cholic acid induce apoptosis into breast cancer cells and interfere with mitochondrion; synthesis, characterization and biological evaluation. Steroids 167:108798","journal-title":"Steroids"},{"key":"855_CR78","doi-asserted-by":"publisher","DOI":"10.3390\/molecules28093856","volume":"28","author":"V Stefanizzi","year":"2023","unstructured":"Stefanizzi V, Minutolo A, Valletta E, Carlini M, Cordero FM, Ranzenigo A, Prete SP, Cicero DO, Pitti E, Petrella G, Matteucci C, Marino-Merlo F, Mastino A, Macchi B (2023) Biological evaluation of triorganotin derivatives as potential anticancer agents. Molecules 28:3856","journal-title":"Molecules"},{"key":"855_CR79","doi-asserted-by":"publisher","first-page":"135","DOI":"10.4149\/gpb_2018042","volume":"38","author":"D Strouhalova","year":"2019","unstructured":"Strouhalova D, Toporova L, Lastovickova M, Macejova D, Bobalova J, Brtko J (2019) Novel insights into the combined effect of triorganotin compounds and all-trans retinoic acid on expression of selected proteins associated with tumor progression in breast cancer cell line MDA-MB-231: proteomic approach. Gen Physiol Biophys 38:135\u2013144","journal-title":"Gen Physiol Biophys"},{"key":"855_CR80","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1016\/j.toxlet.2019.10.004","volume":"318","author":"D Strouhalova","year":"2020","unstructured":"Strouhalova D, Macejova D, Mosna B, Bobal P, Otevrel J, Lastovickova M, Brtko J, Bobalova J (2020) Down-regulation of vimentin by triorganotin isothiocyanates-nuclear retinoid X receptor agonists: a proteomic approach. Toxicol Lett 318:22\u201329","journal-title":"Toxicol Lett"},{"key":"855_CR81","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1016\/S1040-8428(01)00144-5","volume":"41","author":"S-Y Sun","year":"2002","unstructured":"Sun S-Y, Lotan R (2002) Retinoids and their receptors in cancer development and chemoprevention. Crit Rev Oncol Hematol 41:41\u201355","journal-title":"Crit Rev Oncol Hematol"},{"key":"855_CR82","doi-asserted-by":"publisher","DOI":"10.1093\/nar\/gkaf967","volume":"53","author":"I Tambones","year":"2025","unstructured":"Tambones I, Sagar A, Vankova P, Loginov D, Carivenc C, Rochel N, Bourguet W, Man P, Bernad\u00f3 P, le Maire A (2025) New structural insights into the control of the retinoic acid receptors RAR\/RXR by DNA, ligands, and transcriptional coregulators. Nucleic Acids Res 53:gkaf967","journal-title":"Nucleic Acids Res"},{"key":"855_CR83","doi-asserted-by":"publisher","DOI":"10.1016\/j.molstruc.2024.139341","volume":"1318","author":"W Tian","year":"2024","unstructured":"Tian W, Ji M, Yang T, Zhong W, Li Y, Yang M, Yang P, Long X (2024a) Design, synthesis, crystal structure and anticancer activity of organotin (IV)-rhein carboxylates. J Mol Struct 1318:139341","journal-title":"J Mol Struct"},{"key":"855_CR84","doi-asserted-by":"publisher","DOI":"10.1016\/j.jinorgbio.2023.112434","volume":"251","author":"W Tian","year":"2024","unstructured":"Tian W, Zhong W, Yang Z, Chen L, Lin S, Li Y, Wang Y, Yang P, Long X (2024b) Synthesis, characterization and discovery of multiple anticancer mechanisms of dibutyltin complexes based on salen-like ligands. J Inorg Biochem 251:112434","journal-title":"J Inorg Biochem"},{"key":"855_CR85","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1016\/j.toxlet.2016.05.005","volume":"254","author":"L Toporova","year":"2016","unstructured":"Toporova L, Macejova D, Brtko J (2016) Radioligand binding assay for accurate determination of nuclear retinoid X receptors: a case of triorganotin endocrine disrupting ligands. Toxicol Lett 254:32\u201336","journal-title":"Toxicol Lett"},{"key":"855_CR86","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1053\/j.seminoncol.2015.09.002","volume":"43","author":"IP Uray","year":"2016","unstructured":"Uray IP, Dmitrovsky E, Browm PH (2016) Retinoids and rexinoids in cancer prevention: from laboratory to clinic. Semin Oncol 43:49\u201364","journal-title":"Semin Oncol"},{"key":"855_CR87","doi-asserted-by":"publisher","first-page":"253","DOI":"10.1016\/j.ejps.2010.11.015","volume":"42","author":"II Verginadis","year":"2011","unstructured":"Verginadis II, Karkabounas S, Simos Y, Kontargiris E, Hadjikakou SK, Batistatou A, Evangelou A, Charalabopoulos K (2011) Anticancer and cytotoxic effects of a triorganotin compound with 2-mercapto-nicotinic acid in malignant cell lines and tumor bearing wistar rats. Eur J Pharm Sci 42:253\u2013261","journal-title":"Eur J Pharm Sci"},{"key":"855_CR88","doi-asserted-by":"publisher","first-page":"742","DOI":"10.2174\/1568026616666160617091559","volume":"17","author":"CE Wagner","year":"2017","unstructured":"Wagner CE, Jurutka PW, Marshall PA, Heck MC (2017) Retinoid X receptor selective agonists and their synthetic methods. Curr Top Med Chem 17:742\u2013767","journal-title":"Curr Top Med Chem"},{"key":"855_CR89","doi-asserted-by":"publisher","DOI":"10.3390\/ijms19082354","volume":"19","author":"M Watanabe","year":"2018","unstructured":"Watanabe M, Kakuta H (2018) Retinoid X receptor antagonists. Int J Mol Sci 19:2354","journal-title":"Int J Mol Sci"},{"key":"855_CR90","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1093\/abbs\/gmv104","volume":"48","author":"X Zhang","year":"2016","unstructured":"Zhang X, Zhou H, Su Y (2016) Targeting truncated RXR\u03b1 for cancer therapy. Acta Biochim Biophys Sin 48:49\u201359","journal-title":"Acta Biochim Biophys Sin"}],"container-title":["BioMetals"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10534-026-00855-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10534-026-00855-1","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10534-026-00855-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,26]],"date-time":"2026-08-26T12:02:26Z","timestamp":1787745746000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10534-026-00855-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,16]]},"references-count":90,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2026,10]]}},"alternative-id":["855"],"URL":"https:\/\/doi.org\/10.1007\/s10534-026-00855-1","relation":{},"ISSN":["0966-0844","1572-8773"],"issn-type":[{"value":"0966-0844","type":"print"},{"value":"1572-8773","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,16]]},"assertion":[{"value":"8 April 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 July 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 July 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","label":"Conflict of interest","group":{"name":"EthicsHeading","label":"Declarations"}}]}}